Reason: Marketed Without An Approved NDA/ANDA: FDA laboratory analysis found the product to contain undeclared diclofenac and methocarbamol,
Distributed: US NationwideReason: cGMP deviations: Test results confirmed aypical Burkholderia Cepacia were a result of personnel error.
Distributed: Recalled units were distributed to one customer. 100% recovered (113,544 units) and controlled at Denison Pharmaceuticals.Reason: Failed Impurities/Degradation Specifications: failed related substance identified as Eptifibatide dimer.
Distributed: USA nationwide.Reason: Failed Impurities/Degradation Specifications: impurity sulfonic acid adduct of dexamethasone phosphate results were above spec.
Distributed: USA NationwideReason: Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Distributed: Nationwide within the USA.Reason: Presence of Particulate Matter: Presence of particulate matter from the stopper in the drug product.
Distributed: Nationwide within the USA.Reason: Defective Container
Distributed: Nationwide in the USAReason: Defective Container
Distributed: Nationwide in the USAReason: Defective Container
Distributed: Nationwide in the USAReason: Product Mix Up. A bottle labeled as Phenazopyridine HCl tablets USP 100 mg contained Phenobarbital tablets 16.2 mg.
Distributed: Product was distributed to one medical facility.